ArticleLupus science & medicine2026
Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAutoimmune haemolytic anaemia (AIHA) occurs in approximately 5-10% of patients with SLE and it is traditionally associated with higher disease activity, increased damage accrual and reduced survival. SLE management recommendations partially address disease-related haematological manifestations without specific indication for AIHA treatment. Indeed, therapeutic approaches are prevalently extrapolated from the haematology field. In the present report, we aimed at describing a case series of patients with SLE and AIHA successfully treated with anifrolumab (ANF).
methodsWe described patients with SLE treated by ANF with active AIHA at the drug initiation. Clinical and laboratory data were reported in a standardised electronic form, including laboratory evidence of haemolysis. Overall disease activity was assessed by using the SLE Disease Activity Index 2000 (SLEDAI-2k). We collected patients data at baseline (T0), after 1 month (T1) and every 3 months thereafter.
resultsWe included seven patients (6F/1M, median age 61 years (IQR 33), median disease duration 48 months (IQR 72)). All the patients had a positive direct Coombs test and laboratory evidence of active haemolysis at ANF starting. During treatment, we observed a progressive increase in haemoglobin (Hb) levels, with a statistically significant difference compared with baseline after 3 months of treatment (p=0.02). In parallel we registered the increase in RBC count, without the need to perform RBC transfusions after ANF starting. Overall disease activity significantly improved during the follow-up, with significant reduction of mean SLEDAI-2k values after 6 months of treatment (p=0.01).
conclusionIn the present case-series study, we provide the first report about the benefit of ANF in the treatment of SLE-related AIHA, a rare but potentially severe manifestation associated with increased morbidity and mortality. In our cohort, ANF treatment was associated with a rapid and sustained increase in Hb levels, evident already at 1 month and progressively improving up to 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.